ADR Sign up for ETOC alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, M.
Right arrow Articles by Golub, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, M.
Right arrow Articles by Golub, L.
Advances in Dental Research, Vol 12, Issue 2, 152-158
Copyright © 1998 by International & American Associations for Dental Research


Articles

Tetracyclines inhibit protein glycation in experimental diabetes

ME Ryan, NS Ramamurthy, and LM Golub

Department of Oral Biology and Pathology, School of Dental Medicine, State University of New York at Stony Brook 11794-8702, USA.

Glycation of proteins, which is accelerated in the diabetic state, has been implicated in many of the long-term complications of diabetes. This process can be inhibited by members of the tetracycline family of compounds. This novel finding is supported by studies conducted on drug (streptozotocin)induced Type I and genetic (ZDF/Gmi-fa/fa) Type II diabetic rats. These animals were orally gavaged daily with 5 mg of doxycycline and a variety of non-antimicrobial chemically modified tetracycline derivatives for time periods of 3 weeks to 11 months, while control untreated diabetic and nondiabetic animals were gavaged with vehicle alone (2% CMC). Blood and tissue samples were collected and analyzed for glucose and glycated proteins. None of the treatments had any effect on the severity of hyperglycemia or the intracellular glycation of hemoglobin of either Type I or II diabetic animals. However, the tetracycline analogues did affect the extracellular glycation of several proteins such as those found in the serum as well as skin collagen. In the Type II (ZDF) animals, initial mortality (3-5 months) was seen only in the doxycycline-treated animals, associated with infection by tetracycline-resistant micro-organisms, which was eventually surpassed by mortality rates in the untreated diabetics (6-9 months). CMT treatment not only decreased mortality but also increased longevity in the Type II diabetic animals, most likely by preventing the development of a number of long-term complications of uncontrolled diabetes, including glycation of proteins, that eventually lead to the demise of untreated diabetic animals.


This article has been cited by other articles:


Home page
HypertensionHome page
F. A. DeLano and G. W. Schmid-Schonbein
Proteinase Activity and Receptor Cleavage: Mechanism for Insulin Resistance in the Spontaneously Hypertensive Rat
Hypertension, August 1, 2008; 52(2): 415 - 423.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. X. Jiang, J. Lertvorachon, S. T. Hou, Y. Konishi, J. Webster, G. Mealing, E. Brunette, J. Tauskela, and E. Preston
Chlortetracycline and Demeclocycline Inhibit Calpains and Protect Mouse Neurons against Glutamate Toxicity and Cerebral Ischemia
J. Biol. Chem., October 7, 2005; 280(40): 33811 - 33818.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
IADR Journals Advances in Dental Research ®
Journal of Dental Research ® Critical Reviews (1990-2004)
Copyright © 1998 Institutional Access Guidelines